"Ramipril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.
| Descriptor ID |
D017257
|
| MeSH Number(s) |
D03.633.100.893
|
| Concept/Terms |
Triatec- Triatec
- Altace
- Zabien
- Ramace
- Tritace
- Acovil
- Delix
|
Below are MeSH descriptors whose meaning is more general than "Ramipril".
Below are MeSH descriptors whose meaning is more specific than "Ramipril".
This graph shows the total number of publications written about "Ramipril" by people in this website by year, and whether "Ramipril" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ramipril" by people in Profiles.
-
Lackland DT. Systolic blood pressure target levels: evidence for benefits in stroke. Hypertension. 2015 Jan; 65(1):39-40.
-
Gradman AH, Basile JN. Recent clinical trials. J Am Soc Hypertens. 2014 Oct; 8(10):770-4; quiz 775-6.
-
Basile J. Lessons learned from the ONTARGET and TRANSCEND trials. Curr Atheroscler Rep. 2009 Sep; 11(5):371-6.
-
Hernandez AF, Harrington RA. Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? CMAJ. 2008 May 06; 178(10):1316-9.
-
Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008 Mar; 26(3):589-99.
-
Pisoni R, Ruggenenti P, Sangalli F, Lepre MS, Remuzzi A, Remuzzi G. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int. 2002 Sep; 62(3):1010-9.
-
Pisoni R, Faraone R, Ruggenent P, Remuzzi G. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. J Nephrol. 2002 Jul-Aug; 15(4):428-30.
-
Basile JN. Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade. J Clin Hypertens (Greenwich). 2001 Sep-Oct; 3(5):315-6.
-
Basile JN. Renal insufficiency predicts cardiovascular disease in high-risk individuals: the benefit of ramipril in the HOPE study. Heart Outcomes and Prevention Evaluation. J Clin Hypertens (Greenwich). 2001 Jul-Aug; 3(4):256-7.
-
Simunic M, Rumboldt Z, Ljutic D, Sardelic S. Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients. J Clin Pharmacol. 1995 Dec; 35(12):1150-5.